TRIAL DETAIL

Rivoceranib Plus Paclitaxel in Patients With Gastrointestinal Stromal Tumor

Drug:
Trial Name:
Rivoceranib Plus Paclitaxel in Patients With Gastrointestinal Stromal Tumor
NCT#:
Conditions:
Gastrointestinal Stromal Tumor
Status:
Recruiting
Phase:
2
Start Date 09/06/2023
Age of Trial (yrs) 1.6
Treatment Phase:
Gleevec-resistant
Drug Category:
VEGFR inhibitor + Microtubule stabilizer
Strategy:
Trial Type:
Specifically GIST and only GIST
Other Protocol IDs:
AMC2301
Sponsor:
Asan Medical Center
Patient Contact:
Study Contact: Ryu Min-Hee, MD, PhD 82-2-3010-5935 miniryu@amc.seoul.kr Study Contact Backup Kim Hyung-Don, MD, PhD 82-2-3010-0236 kimhdmd@amc.seoul.k
Contact email:
Contact Phone:
Randomized:
IV or Oral:
Oral Intravenous
Trial Notes:
A Phase 2 Study of Paclitaxel Plus Rivoceranib in Patients With GIST With a High P-glycoprotein Expression After Failure With at Least Imatinib, Sunitinib and Regorafenib

Partial Eligibility Criteria. See NCT listing for all eligibility criteria.

Description

Inclusion Criteria:

Age 20 years or older, at the time of acquisition of informed consent
Histologically confirmed metastatic and/or advanced GIST with CD117(+), DOG-1(+), or mutation in KIT or PDGFRα gene
P-glycoprotin IHC score > 3 (Tumor tissue with disease progression after regorafenib treatment)
Failed (progressed and/or intolerable) after prior treatments for GIST, including at least imatinib and sunitinib, regorafenib.

Trial Links

Trial Results

Drug Information

Trial Sites

Name
Address
City
State
Zip
Country
Seoul
Songpa-gu
138-736
Republic of Korea